Egyptian biotech startup Reme-D has secured a $500,000 investment from the Global Innovation Fund (GIF). The funding is set to scale the company’s innovative molecular diagnostics technology, designed to make critical testing more affordable and accessible across Africa and the Middle East.
Quick Facts
- Funding: $500,000 from the Global Innovation Fund.
- Impact: Reduces diagnostic operational costs by up to 40%.
- Expansion: Targeting entry into Nigeria and Libya.
Solving Diagnostics with Room-Temperature Tech
Founded in 2022 by Salma Tammam, Reme-D tackles a fundamental challenge in healthcare logistics: the cold chain. Traditional PCR testing kits require constant refrigeration, a major hurdle in regions with inconsistent electricity or limited infrastructure.
By using nanotechnology and lyophilisation (freeze-drying) techniques, Reme-D produces PCR kits that are stable at room temperature. This approach not only eliminates the need for expensive cold-chain logistics but also minimizes reagent waste and significantly improves testing reliability in low-resource environments. According to the company, its solutions have reduced testing times by up to 70% in certain applications.
From Egypt to Pan-African Expansion
Reme-D has already built a significant operational footprint, currently serving 92 healthcare facilities across Egypt, Iraq, Sudan, and Kenya. The company reports that it facilitates testing for approximately 50,000 patients every month.
With the new capital, Reme-D plans to fuel its next growth phase. The primary objectives include commercial expansion into Nigeria and Libya, scaling up its manufacturing capabilities to meet growing demand, and advancing its research and development pipeline. The company is focusing its R&D efforts on diagnostics for genetic diseases, oncology, and maternal health.
About Reme-D
Founded in 2022, Reme-D is an Egyptian biotechnology company developing room-temperature molecular diagnostics. Its mission is to make PCR testing more accessible and affordable in resource-limited settings by eliminating the need for cold-chain logistics.
Source: Wamda
